Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : NVO crawled time : 04:20 save search
Global Glucagon-like Peptide 1 (GLP-1) Market Report 2023: Key Players Include Pfizer Inc., AstraZeneca PLC, Sanofi, Novo Nordisk Among Others
Published: 2023-11-11 (Crawled : 04:20) - prnewswire.com
SNY | News | $45.39 -1.56% -1.58% 4.3M
|
Health Technology
| Email alert
Add to watchlist
LLY | $745.95 -0.64% -0.81% 1.3M
|
Health Technology
| Email alert
Add to watchlist
AZN | $68.36 -0.25% -0.25% 3.6M
|
Health Technology
| Email alert
Add to watchlist
NVO | $122.75 -1.43% 0.65% 2.7M
|
Health Technology
| Email alert
Add to watchlist
AZNCF | $138.24 -1.36% -4.19% 800
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
| Email alert
Add to watchlist
report astrazeneca global market
Insulin Pump Market - Global Outlook and Forecast 2023-2028: New Product Launches and Technological Advances in Diabetes Care Present Opportunities
Published: 2023-03-04 (Crawled : 04:20) - prnewswire.com
PODD | $164.73 -0.92% -0.94% 590K
|
Health Technology
| Email alert
Add to watchlist
NVO | $122.75 -1.43% 0.65% 2.7M
|
Health Technology
| Email alert
Add to watchlist
care global diabetes insulin market
DICERNA INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Dicerna Pharmaceuticals, Inc. - DRNA
Published: 2021-11-20 (Crawled : 04:20) - prnewswire.com
NVO | $122.75 -1.43% 0.65% 2.7M
|
Health Technology
| Email alert
Add to watchlist
Investigational 2 mg Dose of Ozempic® (semaglutide) Injection Demonstrates Superior Reductions in Blood Sugar vs Ozempic® 1 mg in Adults With Type 2 Diabetes in a Phase 3 Trial
Published: 2021-06-26 (Crawled : 04:20) - prnewswire.com
NVO | $122.75 -1.43% 0.65% 2.7M
|
Health Technology
| Email alert
Add to watchlist
diabetes blood injection phase 3 trial
Investigational 2.0 mg dose of Ozempic® (semaglutide) demonstrates superior reductions in blood sugar vs Ozempic® 1.0 mg in adults with type 2 diabetes in a phase 3 trial
Published: 2021-06-26 (Crawled : 04:20) - globenewswire.com
NVO | $122.75 -1.43% 0.65% 2.7M
|
Health Technology
| Email alert
Add to watchlist
diabetes blood phase 3 trial
Gainers vs Losers
| 60% | 40% |
Top 10 Gainers
AGBA | News | $1.03 157.5% 57.94% 120M
|
Finance
ZCMD | $1.45 5.84% 52.1% 2.3M
|
Commercial Services
INVO | $1.52 100.0% 51.13% 5M
|
Health Technology
ISPC | $0.421 97.65% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.5 45.65% 470K
|
OST | $0.509 23.81% 45.26% 90K
|
GDHG | $0.263 21.76% 40.66% 3.1M
|
XPON | News | $3.15 63.21% 37.74% 16M
|
TIRX | $0.8 65.02% 30.74% 58M
|
BNTC | News | $6.82 42.08% 30.64% 3.5M
|
Health Technology
Your saved searches
Save your searches and get alerts when important news are released.